Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424135 | 0.77 | ADRA1D (0.50) | ALDH1A1MAPK1KMT2AADRA1DADRA1A | |
| SCHEMBL20755090 | 0.77 | LMNA (0.38) | CA2POLBALDH1A1 | |
| SCHEMBL13998646 | 0.77 | ADRA1D (0.50) | ALDH1A1MAPK1KMT2AADRA1DADRA1A | |
| SCHEMBL11097027 | 0.77 | CA2 (0.44) | CA2POLBALDH1A1ADRA1DADRA1A | |
| SCHEMBL11475106 | 0.77 | CA2 (0.44) | CA2POLBADRA1DADRA1AADRA1B | |
| SCHEMBL6981978 | 0.77 | CA2 (0.41) | MAP3K14CA2POLBALDH1A1MAPK1 | |
| SCHEMBL6981984 | 0.77 | CA2 (0.41) | MAP3K14CA2POLBALDH1A1MAPK1 | |
| SCHEMBL15870252 | 0.76 | CYP11B1 (0.39) | BRD4CREBBPMAPK1KMT2ATDP1 | |
| SCHEMBL16413927 | 0.75 | SIRT1 (0.45) | POLBALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL7636369 | 0.75 | PARP1 (0.43) | BRD4CREBBPALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | BRD4 2424/4885CREBBP 1057/4885MAP3K14 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.